Novartis to buy Avexis in $8.7 billion gene-therapy deal – SFGate
Chemical & Engineering News |
Novartis to buy Avexis in $8.7 billion gene–therapy deal
SFGate Novartis has agreed to acquire Avexis for $8.7 billion to gain a promising drug to treat a rare disease that afflicts infants, hastening a shift toward gene therapy and precision medicines. Shareholders of the Illinois biotech company will receive $218 … How These Gene Therapy Stocks Benefit From Novartis-AveXis Deal Novartis to expand gene therapy pipeline with acquisition of AveXis for $8.7 billion Novartis signs $8.7bn gene therapy deal |
